Applicabillity of noninvasive biomarkers in prostate cancer diagnosis.

Raluca Dumache, Maria Puiu, Dragos Miclea, Bogdan Bumbacila, Florin Miclea

Abstract read

In one paragraph

Article in Maedica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 79% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Raluca DumacheDepartment of Biochemistry, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.

Maria Puiu

Dragos Miclea

Bogdan Bumbacila

Florin Miclea

Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer represents the second leading cause of male cancer-related deaths worldwide. Better indicators of the presence of prostate cancer are needed to avoid unnecessary treatment, predict disease course and develop more effective therapy. Many molecular biomarkers have been described in human serum, urine, seminal fluid and histological specimens that exhibit varying capacities to detect prostate cancer and predict disease course.

Indexed as

digital rectal examination (DRE)proliferative inflammatory atrophy (PIA)prostate cancer (PCa), benign prostatic hyperplasia (BPH), prostate-specific antigen (PSA), biomarkersprostatic intraepithelial neoplasia (PIN)

Identifiers

PMID21977117

PMCPMC3150079

OpenAlexW2171758032

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.